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  10 
Abstract 11 
Purpose: To develop topical formulations of Clerodendrum petasites S. Moore (CP), and to optimise 12 
the skin permeability and topical bioavailability of the active phenolic compounds therein.  13 
Methods: The skin uptake and delivery of active compounds from two formulations, an oil-in-water 14 
cream and a lotion (both containing 10% w/w CP extracts), were examined (a) in vitro using pig skin, 15 
and (b) in vivo in human volunteers. Stratum corneum (SC) was collected by tape stripping and the 16 
compounds were detected and quantified by high performance liquid chromatography coupled with 17 
either mass spectrometry (HPLC-MS) or ultraviolet and photodiode array (HPLC-UV-PDA) detection.  18 
Results: From the in vitro results, vanillic acid, verbascoside, nepetin and hispidulin, were chosen as 19 
potential phenolic actives for topical delivery optimisation from the formulations. In vivo, vanillic 20 
acid, nepetin and hispidulin were appreciably taken up into the SC within 6 hours, while 21 
verbascoside did not penetrate beyond the most superficial layers.  No significant differences in 22 
delivery were observed between the two formulations, both of which were well tolerated. 23 
Conclusions:  The detected topical absorption of hispidulin, nepetin, and vanillic acid, from the cream 24 
and lotion vehicles investigated, suggest that these compounds are potentially active compounds in 25 
Thai traditional medicine for the treatment of a wide range of skin diseases.  26 
Keywords: Clerodendrum petasites S. Moore, hispidulin, skin permeation, topical bioavailability, 27 
mass spectrometry. 28 
Chemical compounds: Vanillic acid (PubChem CID: 8468); verbascoside (PubChem CID: 5281800); 29 
nepetin (PubChem CID: 5317284); hispidulin (PubChem CID: 5281628). 30 
Abbreviations: CP, Clerodendrum petasites S. Moore; HPLC, high performance liquid 31 
chromatography; MS, mass spectrometry; PDA, photodiode array; SC, stratum corneum; TEWL, 32 
transepidermal water loss; KSC,V, SC-vehicle partition coefficients; LOQ, limit of quantification.  33 
Introduction 34 
Clerodendrum petasites S. Moore (Lamiaceae, English name: One Root Plant, Thai name: Thao-Yaai-35 
Mom) is commonly found in the middle, north-eastern and southern parts of Thailand. It is 36 
extensively prepared as a tea, alcoholic extract, cigarette, or powder for oral administration to treat 37 
asthma (Hazekamp et al., 2001; Panthong et al., 2003; Panthong et al., 1986), inflammation 38 
(Panthong et al., 1986), fever, cough and vomiting (Panthong et al., 2003; Thai traditional medical 39 
textbook: Paet-Ta-Ya-Saat-Song-Kror 2007) (S. Tungjitaruen, pers. comm., 2011). For topical use, the 40 
traditional dosage form is a poultice to treat skin diseases, such as rash, abscess, urticaria, 41 
snakebites and insect bites (Panthong et al., 2003; Pongboonrot, 1965; Thai traditional medical 42 
textbook: Paet-Ta-Ya-Saat-Song-Kror 2007) (T. Tipcharoentham, pers. comm., 2011; S. Tungjitaruen, 43 
pers. comm., 2011). Alcohol, especially Thai rice whisky, is often used as a dispersing vehicle in many 44 
formulations before application. At present, only the plant itself and powders therefrom are found 45 
on the market with poor reliability and reproducibility with respect to the active ingredients. These 46 
forms are also inconvenient to use and transport. The nature of the active species remain poorly 47 
characterized (Hazekamp et al., 2001; Klaiklay, 2009; Singharachai et al., 2011; Thongchai et al., 48 
2007) and there is no information concerning the topical bioavailability of active species from this 49 
plant.  50 
A preliminary study, reported elsewhere (Thitilertdecha et al., 2014), identified eleven phenolic 51 
compounds, vanillic acid, 4-coumaric acid, ferulic acid, verbascoside, nepetin, luteolin, chrysin, 52 
naringenin, hesperetin, apigenin, and hispidulin, in an ethanolic (80%) extract of the plant, predicted 53 
their maximum skin fluxes (Jmax) and measured skin absorption in vitro from a 50% w/w CP paste and 54 
a 50 mg∙mL-1 CP solution. In the present study, suitable dosage forms for topical delivery to the skin 55 
were developed and optimised, and the topical bioavailability of the active substances was 56 
determined in vivo in human volunteers. 57 
 58 
Materials and methods 59 
1 Plant materials 60 
Dried samples of CP were obtained from the Ayurved Siriraj Manufacturing Unit of Herbal Medicines 61 
and Products, Center of Applied Thai Traditional Medicine (CATTM), Faculty of Medicine Siriraj 62 
Hospital, Mahidol University, Thailand. An extract of powdered plant was produced by maceration 63 
using 80% ethanol and subsequently lyophilized to dryness (Alpha 2-4 Isc., Martin Christ Company, 64 
Germany).  Prior to use, the extracts were kept separately in light protective and airtight containers 65 
and stored in a desiccator at room temperature. Batch-to-batch consistency of the ethanolic extracts 66 
was confirmed by quantification of phenolic constituents as described previously (Thitilertdecha et 67 
al., 2014).     68 
2 Chemicals and reagents 69 
Vanillic acid (Fluka Analytical, China), verbascoside, nepetin (Extrasynthese, France), and hispidulin 70 
(Tocris Bioscience, UK), were of analytical grade.  71 
Mobile phases for HPLC-MS and HPLC-PDA consisted of chromatography grade acetonitrile (Fisher 72 
Scientific, UK), deionized water (Millipore, MA, USA) and MS grade acetic acid (Fluka Analytical, 73 
Germany). Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl, Acros Organics, USA), tris 74 
(hydroxymethyl) aminomethane (Trizma® base, Sigma-Aldrich, USA), methanol, and ethanol (Sigma-75 
Aldrich, USA) were of analytical grade. Acetone was laboratory grade.  76 
Excipients of the topical formulations were propyl paraben (propyl 4-hydroxybenzoate), stearyl 77 
alcohol (1-octadecanol), Tween 60 (polyethylene glycol sorbitan monostearate), Span 60 (sorbitan 78 
monooctadecanoate), glycerol, mineral oil, and triethanolamine (TEA) (Sigma-Aldrich, USA), methyl 79 
paraben (methyl 4-hydroxybenzoate) and cetyl alcohol (Fluka Analytical, Germany), butylated 80 
hydroxytoluene (BHT) (SAFC, Germany), propylene glycol (Acros Organics, UK), glycerol 81 
monostearate-self emulsifier (GMS-SE) and Carbopol ultrez 21 (acrylates/C10-30 alkyl acrylate 82 
crosspolymer (The Lubrizol Corporation, USA).   83 
3 Skin for the in vitro permeation study 84 
Fresh porcine abdominal skin was obtained from B&J Pigs Ltd, Somerset, UK.  Excess hair was 85 
carefully trimmed using scissors. After cleaning with running cold water, the skin was dermatomed 86 
(Zimmer electric dermatome, Oklahoma, USA) to a nominal thickness of 750 µm. The dermatomed 87 
skin was sealed in a plastic bag and stored at -20○C until use.  88 
4 Human subjects 89 
Six healthy volunteers aged between 25 and 31 years (4 females and 2 males), with no history of skin 90 
disease, no visible skin abnormalities and no prior skin treatment in the preceding 4 weeks, 91 
participated in the study. Written informed consent was obtained from each subject before the 92 
study, which was approved by the University of Bath Ethics Committee.  93 
5 Cream and lotion formulations 94 
Excipients of the cream and lotion are in Table I. They were formulated and then stored in a light-95 
protective and airtight container at 4○C. 96 
Table I: Excipients of cream and lotion formulations. 97 
Excipient 
Quantity (%, w/w) 
10% CP cream Control  
cream 
10% CP lotion Control 
lotion 
C. petasites  
(dried ethanolic extracts) 
10 - 10 - 
GMS-SE  5 5 1 1 
Cetyl alcohol 5 5 1.5 1.5 
Stearyl alcohol 2.5 2.5 - - 
Mineral oil 15 15 15 15 
Tween 60 4 4 4 4 
Span 60 1 1 1 1 
Carbopol ultrez  
(2%  w/w stock gel)* 
3 3 3 3 
Propylene glycol 4 4 3 3 
Glycerol 3 3 - - 
Concentrated paraben**  1% v/w 1% v/w 1% v/w 1% v/w 
BHT 0.02 0.02 0.02 0.02 
Purified water qs. to 100 100 100 100 
* Pre-preparation required before formulating cream and lotion. 98 
** A preservative mixture of methyl paraben (10 g) and propyl paraben (2 g) in propylene glycol (100 mL). 99 
6 Analytical methods 100 
6.1 High performance liquid chromatography coupled with mass spectrometry (HPLC-MS) 101 
HPLC-MS was performed on a Shimadzu HPLC-2010A HT system (Shimadzu Corp., Kyoto, Japan) 102 
consisting of an autosampler, vacuum degasser, and UV detector operating at 260 and 330 nm. 103 
The HPLC was interfaced to a Shimadzu MS-2010EV system (Shimadzu Corp., Kyoto, Japan) with a 104 
dual source of electrospray ionization and atmospheric pressure chemical ionization (ESI/APCI, DUIS-105 
2010, Japan). Ionization was achieved in both negative- and positive-ion-modes with the detector 106 
voltage set at 1.5 kV. Nitrogen was used as a nebulising gas, heated to 480○C and delivered at a flow 107 
rate of 1.5 L·min-1. MS signals collected in the single ion-monitoring (SIM) mode were used for 108 
quantification of individual compounds.  109 
The column used was a Dionex Acclaim® 120 (C18, 5 µm, 150 x 4.6 mm i.d.). The mobile phase was a 110 
combination of acetonitrile (A) and 0.1% aqueous acetic acid (v/v, B) with an optimized gradient 111 
system of 20% A for 9 min, 20-60% A for 6 min, 60% A for 5 min, 60-95% A for 10 min, 95% A for 5 112 
min and 20% A for 25 min. The injection volume was 20 µL and the flow rate was 0.5 mL·min-1. The 113 
column temperature was maintained at 35○C throughout the analysis. All data acquired were 114 
processed by the LabSolutions LCMS Software (Shimadzu Corp., Kyoto, Japan). 115 
6.2 HPLC coupled to ultraviolet and photodiode array detection (HPLC-UV-PDA) 116 
HPLC-UV-PDA was carried out using an ASI-100 automated sample injector, thermostatted column 117 
compartment TCC-100 and PDA-100 photodiode array detector (Dionex® Ltd., UK). The UV detection 118 
wavelengths were 260 and 330 nm for quantification and the maximum wavelengths (λmax) of each 119 
peak were confirmed by a wavelength scan from 240 to 360 nm. 120 
A HiQ Sil C18 HS column (C18, 5 µm, 150 x 4.6 mm i.d., Kyatech, Japan) was used at a temperature of 121 
35○C. The HPLC-PDA conditions differed only slightly from those optimized for HPLC-MS. Acetonitrile 122 
(A) and a mixture of 0.1% aqueous acetic acid and acetonitrile (v/v, 80:20, B) were combined as the 123 
mobile phase in a gradient system of 0% A for 9 min, 0-50% A for 6 min, 50% A for 5 min, 50-94% A 124 
for 10 min, 94% A for 5 min and 0% A for 25 min with a flow rate of 0.5 mL·min-1. 20 µL of each 125 
sample was injected. Chromatograms were interpreted with Chromeleon software (Dionex® Ltd., 126 
UK). Retention times (tR) and UV peak detection using HPLC-PDA were compared with those using 127 
HPLC-MS.   128 
7 In vitro skin penetration experiments 129 
The skin permeation of compounds in the plant extracts was determined in vertical, glass Franz 130 
diffusion cells (PermeGear, Inc., Bethlehem, PA, USA). The exposed membrane surface area was 1.77 131 
cm2 and the receptor solution was 7.5 mL of a mixture of ethanol and 5 mM Tris buffer in ratio of 1:4 132 
v/v, at pH 7.3 (i.e., slightly less than 7.4 due to the presence of ethanol). Frozen dermatomed pig 133 
abdominal skin was thawed for 30 minutes before use and examined visually for punctures or 134 
defects. The skin was stripped with one adhesive tape (3.5 cm x 3.5 cm, Scotch book tape, 3M, MN, 135 
USA) to remove SC disjunctum before being mounted into the Franz cell. After temperature 136 
equilibration at 37○C, approximately 0.2 g of the formulations was applied to the skin surface and 137 
occluded with Parafilm™ (Bemis Company, Inc., Neenah, WI). After 6 hours, the whole receptor 138 
solution volume was removed and stored at 4○C under light protection before quantitative analysis. 139 
The skin was subsequently taken out of the Franz cell and the remaining formulation was removed 140 
with an isopropyl alcohol swab (70% isopropyl alcohol; Sterets®, Medlock Medical Ltd., UK). The skin 141 
was then pinned to a polystyrene board and left to air dry for 3 hours. A template with a circular 142 
aperture (1.4 cm diameter, Scotch book tape, 3M, MN, USA) was positioned over the treated area 143 
before stripping the SC using tapes. Six replicates were performed with each formulation. 144 
8 In vivo skin penetration experiments 145 
The passive diffusion of constituents of the two plant extract formulations into the SC of healthy 146 
volunteers was studied over 2 days. On day 1, the first formulation was applied to one arm; on day 147 
2, the second formulation was applied to the other. The ventral forearms were cleaned with an 148 
alcohol wipe and the subject was acclimatized to the treatment venue for 30 minutes. Four skin sites 149 
(3 treated + 1 blank, control) were delineated on each arm at least 4 cm above the wrist and a 150 
minimum of 4 cm below the elbow. Each treatment site (6 cm2 in area, Figure 1) was demarcated 151 
with a rectangular frame cut from a self-adhesive foam (1.57 mm in thickness; 3M, USA) and applied 152 
to the ventral forearm with the long dimension oriented across the forearm. One tape strip was 153 
discarded before drug application to remove SC disjunctum. Good contact between tape and skin 154 
was ensured by running a weighted roller (6 cm wide, 140 g cm-2) over the tape several times before 155 
its removal. A fingertip cut from a laboratory glove (nitrile and powder-free glove; Kimtech, UK) was 156 
used to distribute the cream/lotion over the demarcated area. The sites were treated at 45-minute 157 
intervals. Approximately 0.2 g of the product (containing 10% w/w CP extracts) was applied to sites 158 
1-3, while the blank (cream/lotion base without CP) was applied to site 4. The actual amount applied 159 
was determined by weighing the fingertip before and after drug application. All sites were occluded 160 
by covering the foam frame with Parafilm™ secured to the skin with a self-adhesive fabric dressing 161 
(Mefix®, SCA Molnlycke Ltd., Sweden). The drug application time was 6 hours.  162 
At the end of the experiment, the dressing, Parafilm™ and foam frame were removed. Excess 163 
cream/lotion was gently wiped away with tissue (Fort James Ltd., UK), and then swabbed three 164 
times with alcohol wipes. The skin was finally left to air dry for 1 minute before a new thin foam 165 
frame (dimension of the cut out inside are 1.5 cm x 2 cm, 0.75 mm in thickness; 3M, USA) was placed 166 
over each cleaned site in the same position as the original frame (Figure 1). Subsequently, the tape 167 
stripping procedures were commenced. 168 
 169 
 170 
Figure 1: Illustration of drug application and tape strip area (adapted from reference (N'Dri-Stempfer 171 
et al., 2009)). 172 
9 Tape stripping and tape extraction 173 
Tape stripping was performed at the end of the in vitro and in vivo percutaneous experiments. The 174 
stripped area was delineated by the templates.  First, transepidermal water loss (TEWL) was 175 
measured (AquaFlux® evaporimeter, Biox System Ltd., UK) to obtain an initial value. An adhesive 176 
tape strip (2.5 cm x 2.5 cm; Permacel J-LAR®) was applied to the skin and pressed firmly down using 177 
the weighted roller. The tape was removed quickly from the skin and TEWL was measured again. The 178 
procedure was repeated until TEWL reached 4 times the initial value or when 30 strips had been 179 
taken.  180 
The mass of skin removed on each tape was determined by weighing the tapes on a microbalance 181 
(Satorius model SE2-F, Sartorius AG, Germany), before and after application to the skin. Before 182 
weighing, the tapes were stored at room temperature for at least 12 hours and static electricity was 183 
discharged (R50 discharging bar and ES50 power supply, Eltex Elektrostatik GmbH, Weil am Rhein, 184 
Germany).  185 
After weighing, the tapes were grouped for methanol extraction. The first and second tapes were 186 
individually analysed, while the remaining tape strips were combined into groups of 2-4 tapes 187 
depending on the total number collected in each experiment. Groups containing 1-2 tapes were 188 
extracted with 1 mL of methanol, those with 3-4 tapes were extracted into 1.5 mL. Extraction 189 
involved shaking overnight (IKA HS 260 Basic shaker, IKA® Werke GmbH & Co., KG, Germany). The 190 
Drug application area 
= 6 cm2 
Tape strip area 
= 3 cm2 
Foam frame 
Foam frame 
extracted solutions were then filtered through a 0.45 µm nylon membrane, and either directly 191 
injected, or concentrated by freeze-drying before injection into an HPLC-MS or HPLC-PDA. If not 192 
processed at once, the samples were freeze-dried and stored at 4○C before analysis. 193 
10 Statistical analysis 194 
All statistical analyses were performed using GraphPad Prism® version 5 (GraphPad Software Inc., 195 
CA, USA). Calibration curves were assessed by linear regression. Datasets were expressed as mean ± 196 
SD (standard deviation) and compared for statistical significance at P ≤ 0.05 with two-way ANOVA 197 
and Bonferroni post-tests. 198 
  199 
Results 200 
1 In vitro percutaneous absorption of CP constituents from a cream and a lotion 201 
On the basis of preliminary results (Thitilertdecha et al., 2014), four compounds, vanillic acid, 202 
verbascoside, nepetin and hispidulin, all known to be present in the CP extract, were selected to 203 
monitor and compare the performance of the two formulations. 204 
Equivalent sets of sample and control experiments were conducted with a 6-hour application to 205 
allow comparison with the results of in vivo studies carried out in human volunteers. 206 
Table II: Quantities per unit area (and % penetrationa) of vanillic acid, verbascoside, nepetin and 207 
hispidulin detected in SC and in the receptor solution after 6 hours (average ± SD, 6 replicates).  208 
Compound 
10% w/w CP cream  10% w/w CP lotion 
Quantity 
(nmol·cm-2) 
% penetration  Quantity 
(nmol·cm-2) 
% penetration 
In SC In receptor   In SC In receptor  
Vanillic acid      0.6 ± 0.3      0.6 ± 0.5      2.1 ± 1.5       0.6 ± 0.2      0.4 ± 0.3      1.3 ± 0.9 
Verbascoside      0.3 ± 0.02b - -       0.5 ± 0.03b - - 
Nepetin      0.8 ± 0.6      0.1 ± 0.02      0.1 ± 0.01       0.9 ± 0.6      0.1 ± 0.03      0.1 ± 0.02 
Hispidulin      3.0 ± 0.4      1.1 ± 0.8 0.24 ± 0.19       2.4 ± 0.4      0.7 ± 0.3      0.2 ± 0.1 
a = Values were determined from the ratio of the cumulative amount of compound in the receptor solution to its original 209 
content in the formulation applied (calculated from the quantities of the compounds in a dried ethanolic extract, the 210 
amount of the dried extract used in the formulation, and the amount of the formulation applied). 211 
b = only 3 replicates were measurable. 212 
 213 
All compounds except verbascoside were delivered from both cream and lotion vehicles and were 214 
detected in the receptor phase after 6 hours (Table II). Results from tape-stripping (Table II) were 215 
consistent with these findings. Vanillic acid and hispidulin were taken up into the SC and crossed the 216 
skin well. Verbascoside was only found in the SC and was not percutaneously absorbed. Little 217 
difference was observed between the two formulations. 218 
2 In vivo SC uptake of CP constituents from a cream and a lotion  219 
Cumulative amounts of vanillic acid, nepetin and hispidulin taken up into the SC of the individual 220 
volunteers from the cream and lotion are presented in Table III. Transport of hispidulin from the 221 
cream (1 nmol·cm-2) was approximately double that of nepetin and vanillic acid (0.4, and 0.3 222 
nmol·cm-2, respectively). The penetration of these three compounds from the lotion was similar to 223 
those from the cream. Verbascoside was not detectable in the SC following application of either the 224 
cream or the lotion. Reproducibility was good and the robustness of the in vivo methodology was 225 
demonstrated by low inter-subject variability: CVs were less than 29% for hispidulin, 44% for vanillic 226 
acid, and 55% for nepetin from both formulations.  227 
Table III: Amounts of vanillic acid, verbascoside, nepetin and hispidulin taken up into the SC after a 6-228 
hour application of a cream and a lotion to human volunteers. 229 
Volunteer 
number 
Amount in SC 6-hour post application of 10% w/w CP cream 
(average ± SD, nmol·cm-2, n=3) 
Vanillic acid Verbascoside Nepetin Hispidulin 
1  0.3 ± 0.1 - 0.4 ± 0.1           0.7 ± 0.1 
2  0.3 ± 0.1 - 0.5 ± 0.2           1.1 ± 0.1 
3  0.4 ± 0.1 - 0.6 ± 0.1           1.3 ± 0.2 
4    0.2 ± 0.02 -      0.6 ± 0.003   0.9 ± 0.03 
5    0.2 ± 0.04 - 0.6 ± 0.1           0.8 ± 0.1 
6   0.6 ± 0.1a -     0.1 ± 0.01a  1.1 ± 0.1a 
Average  0.3 ± 0.1 - 0.4 ± 0.2           1.0 ± 0.2 
%RSD 43.1 - 48.5 23.1 
aMeasured with MS detection. 230 
Volunteer 
number 
Amount in SC 6-hour post application of 10% w/w CP lotion 
 (average ± SD, nmol·cm-2, n=3) 
Vanillic acid Verbascoside Nepetin Hispidulin 
1           0.5 ± 0.1 -  0.4 ± 0.02           0.7 ± 0.2 
2           0.4 ± 0.1 -           0.6 ± 0.1           1.2 ± 0.2 
3   0.4 ± 0.04 -           0.6 ± 0.2           1.1 ± 0.1 
4   0.2 ± 0.03 -           0.6 ± 0.1           0.9 ± 0.1 
5  0.3 ± 0.1a -           0.4 ± 0.3a  0.6 ± 0.1a 
6  0.5 ± 0.1b -  0.05 ± 0.02b           0.8 ± 0.2b 
Average           0.4 ± 0.1 -           0.5 ± 0.3           0.9 ± 0.2 
%RSD 29.0 - 54.9 28.5 
aTwo sites were measured with UV detection, a third with MS; b = 3 sites were measured with MS detection. 231 
When nepetin was detected by MS in volunteer 6, the level observed was small. While there should 232 
be little or no difference between the PDA and MS assays, it is possible that the PDA peak for 233 
nepetin was subject to interference by other compounds in the plant extract with a similar retention 234 
time (e.g., luteolin). It is possible, therefore, that the nepetin quantities found in volunteers 1-5 235 
using PDA may over-estimate the actual amounts present in the SC. In contrast, no interfering peaks 236 
with those of vanillic acid and hispidulin were apparent.  237 
Figure 2 compares in 1 subject the SC concentration versus depth profiles of vanillic acid, nepetin, 238 
and hispidulin, respectively, from the two formulations after a 6-hour application. Vanillic acid 239 
showed a more or less constant low concentration throughout the SC. Concentration-depth profiles 240 
of nepetin and hispidulin were similar to those reported previously for other, unrelated compounds 241 
(Alberti et al., 2001; Herkenne et al., 2007; Wagner et al., 2000). There were consistent profiles 242 
observed for the 6 volunteers (see the Supplementary Data) except for nepetin in volunteer 6 when 243 
the MS assay was used.   244 
 245 
Figure 2: SC concentration versus depth profiles of vanillic acid, nepetin, and hispidulin in 1 subject 246 
after a 6-hour application of 10% w/w CP cream (panel A) and 10% w/w CP lotion (panel B). 247 
 248 
  249 
Discussion 250 
Preliminary in vitro percutaneous penetration studies determined the topical absorption of the 251 
principal phenolic actives in CP (Thitilertdecha et al., 2014). Vanillic acid, nepetin and hispidulin were 252 
the three compounds showing the most substantial absorption and thus were the likeliest 253 
candidates for eliciting CP’s antimicrobial (Delaquis et al., 2005; Sultana and Afolayan, 2007), anti-254 
inflammatory (Clavin et al., 2007; Gil et al., 1994; Kim et al., 2011), and antioxidant activities (Kang et 255 
al., 2009). Verbascoside was included in the present study because of its apparent affinity to the SC 256 
and because its structure and physicochemical properties predict that it is a poor permeant (i.e., it 257 
serves as a “negative” control for the other three compounds). 258 
An o/w cream and an o/w lotion containing excipients expected to enhance skin penetration (e.g., 259 
propylene glycol, glycerol, and the surfactants Tween 60 and Span 60) were formulated to improve 260 
permeability of the four selected actives. The concentration of CP was controlled at 10% by weight 261 
which has been reported as the maximal concentration of plant ethanolic extracts in topical 262 
products without measurable toxicity (Diwan et al., 2001). A secondary objective was to avoid the 263 
use of ethanol as this co-solvent may alter the barrier function and irritate the skin. Hispidulin 264 
penetrated in the greatest amount followed by vanillic acid and nepetin. Verbascoside was only 265 
taken up into the SC and was not percutaneously absorbed. No significant difference was observed 266 
between the two formulations, the excipients of which were similar. 267 
The theoretically predicted uptake (determined from the calculated Jmax values determined in the 268 
preliminary study (Thitilertdecha et al., 2014)) can be qualitatively compared with the experimental 269 
data in Table II. Verbascoside’s poor permeability was as anticipated (predicted uptake of only 0.003 270 
nmol·cm-2). Vanillic acid was indeed well-absorbed but its penetration was much lower than that 271 
expected from the predicted Jmax (440 nmol·cm-2). This is most likely because the formulations 272 
contained vanillic acid at much less than its saturation concentration. The same conclusion fits with 273 
the results for nepetin and hispidulin, the experimental absorption of which was lower than that 274 
predicted from their calculated Jmax values (1.2 and 2.4 nmol·cm-2, respectively).  275 
Although delivery of the compounds from the CP cream and lotion were less than those predicted 276 
from saturated solution, the percentage penetration observed (Table II) was greater than that from 277 
the hydroalcoholic solution used in the preliminary study (Thitilertdecha et al., 2014). This may be 278 
due to the presence of surfactants in the cream and lotion formulations facilitating the solubilisation 279 
of the compounds in the SC.  280 
The in vivo and in vitro SC uptake data are compared in Figure 3 and show good overall agreement. 281 
SC uptake in vitro was generally higher than in vivo and statistically significant differences were 282 
found for nepetin and hispidulin (P < 0.01 and < 0.001, respectively). Verbascoside taken up into the 283 
SC never reached the analytical LOQ in vivo. Thus, while quantitative extrapolation from in vitro 284 
results to the in vivo situation may not be possible, it appears that in vitro experiments would be 285 
useful for formulation development. 286 
 287 
Figure 3: Amounts (mean ± SD) of vanillic acid, verbascoside, nepetin and hispidulin taken up into 288 
the SC from cream and lotion formulations in vitro and in vivo (filled and open bars, respectively; n = 289 
6). 290 
The cream and lotion bases without plant extracts were stable for at least 1 month under 291 
accelerated conditions at 30○C and 75%RH (as recommended for Thailand by the World Health 292 
Organization). These stability tests were conducted at the Center of Applied Thai Traditional 293 
Medicine, Faculty of Medicine Siriraj Hospital in Thailand. However, the formulations containing the 294 
plant extracts were unstable under the same stress conditions. The plant extracts in the lotion 295 
separated more easily from the base than in the cream. Nevertheless, the separation was reversible 296 
upon shaking. Formulation reproducibility was shown by consistent viscosity profiles between 297 
different batches of the two formulations.  298 
  299 
Conclusion 300 
This is the first investigation of the topical delivery of products containing extracts of C. petasites in 301 
vitro and in vivo in humans. Four naturally-occurring active compounds in the plant, vanillic acid, 302 
verbascoside, nepetin and hispidulin, were identified as relevant actives for skin permeation studies. 303 
The four compounds, based on their uptake and penetration into the skin, together with their 304 
known biological activities, may be considered as feasible candidates for the development of novel 305 
and effective antimicrobial, anti-inflammatory, and antioxidant formulations and support the 306 
ethnomedical uses of C. petasites in Thailand. It was also found that the in vitro model and the tape-307 
stripping method were robust and effective to establish guidelines for topical delivery studies of 308 
natural products. Both lotion and cream formulations containing C. petasites extracts are potential 309 
standardised medicines for the Thai market, but show some stability problems, that require further 310 
development. Overall, this study demonstrates a feasible approach to developing a series of topical 311 
medicines that retain the herbal ingredients that many patients value whilst achieving higher levels 312 
of standardisation and quality than currently exist on the market. 313 
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